ArticleNeuropsychiatric disease and treatment2025
Brexpiprazole in the Management of Schizophrenia: A Consensus Report of Best Practices From Acute to Maintenance Treatment.
Article in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brexpiprazole is a second-generation antipsychotic with multiple indications, including the treatment of schizophrenia. As a partial dopamine agonist, brexpiprazole differs from most other antipsychotics, yet uncertainties about its full mechanism of action have led to some ambiguity among prescribers. To address this gap, an international panel of psychiatric experts was organized and convened with funding from Otsuka Pharmaceutical Europe Ltd and H. Lundbeck A/S to discuss the safe and effective use of brexpiprazole across different stages of schizophrenia treatment. Brexpiprazole's pharmacological profile-characterized by balanced binding affinities across norepinephrine, dopamine, and serotonin receptors-contributes to its efficacy in multiple symptom domains, including agitation and negative symptoms. Its tolerable safety profile, marked by minimal activation and minimal sedation and a relatively low risk of long-term cardiometabolic concerns, further supports its clinical utility. Brexpiprazole is a viable first-line therapy in both inpatient and outpatient settings when properly titrated and monitored. Brexpiprazole also serves as an option for different symptom domains in schizophrenia and for patients needing to switch antipsychotics due to inadequate symptom control or intolerable adverse events. Long-term maintenance therapy is essential for relapse prevention in schizophrenia, and when prescribed at appropriate doses for psychotic symptom control, brexpiprazole can provide sustained benefits with minimal long-term safety concerns. This report outlines the consensus panel's recommendations on the optimal initiation and administration of brexpiprazole in management of schizophrenia treatment, including a treatment algorithm, which is supported by a literature review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.